ID   402-91/ET
AC   CVCL_S814
DR   Wikidata; Q54602863
RX   PubMed=21805478;
CC   Selected for resistance to: ChEBI; CHEBI_84050; Trabectedin (Ecteinascidin-743; ET-743).
CC   Sequence variation: Gene fusion; HGNC; HGNC:2726; DDIT3 + HGNC; HGNC:4010; FUS; Name(s)=FUS-DDIT3, TLS-CHOP (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
DI   NCIt; C27781; Myxoid liposarcoma
DI   ORDO; Orphanet_99967; Myxoid/round cell liposarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_S813 ! 402-91
SX   Male
CA   Transformed cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 11
//
RX   PubMed=21805478; DOI=10.1002/ijc.26340;
RA   Uboldi S., Bernasconi S., Romano M., Marchini S., Fuso Nerini I.,
RA   Damia G., Ganzinelli M., Marangon E., Sala F., Clivio L., Chiorino G.,
RA   Di Giandomenico S., Rocchi M., Capozzi O., Margison G.P., Watson A.J.,
RA   Caccuri A.M., Pastore A., Fossati A., Mantovani R., Grosso F.,
RA   Tercero J.C., Erba E., D'Incalci M.;
RT   "Characterization of a new trabectedin-resistant myxoid liposarcoma
RT   cell line that shows collateral sensitivity to methylating agents.";
RL   Int. J. Cancer 131:59-69(2012).
//